Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
RedHill Biopharma Stock Quote

RedHill Biopharma (NASDAQ: RDHL)

$0.45
(7.4%)
$0.03
Price as of April 19, 2024, 3:59 p.m. ET

RedHill Biopharma Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
RDHL -86.02% -99.87% -73.49% -100%
S&P +20.62% +72.50% +11.51% +243%

RedHill Biopharma Company Info

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.